Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Iovance Biotherapeutics Appoints Dan Kirby as

Chief Commercial Officer

SAN CARLOS, Calif., February 10, 2025 -- Iovance Biotherapeutics,

Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating

lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership

team in the newly created role of Chief Commercial Officer, effective today.

"I would like to extend a warm welcome to Dan Kirby on behalf

of the entire Iovance team," stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of

Iovance. "Dan has been instrumental in building and leading cell therapy commercial organizations since the earliest developments

in the field. He is the perfect fit for Chief Commercial Officer as we grow the U.S. launch of Amtagvi and prepare to enter new markets

around the world while also expanding our Proleukin sales."

Prior to joining Iovance, Mr. Kirby led global commercial strategy

for an emerging cell therapy platform of products as Chief Commercial Officer of Orca Bio. From 2018 to 2020, he served as Chief Commercial

Officer at Omeros Corporation (NASDAQ: OMER), overseeing U.S. and EU launch readiness for narsoplimab, a lectin pathway inhibitor, for

hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Previously, he led market access, reimbursement and marketing

efforts for CAR T products as Vice President and Head of US Cell and Gene at Celgene (now Bristol-Myers Squibb; NASDAQ: BMS). He joined

Celgene following the acquisition of Juno Therapeutics, where he was Vice President of Marketing and Market Access. Earlier in his career,

Mr. Kirby was Head of Marketing for Medivation (now Pfizer, NASDAQ: PFE) and held various commercial roles of increasing responsibility

during a 14-year tenure at Amgen (NASDAQ: AMGN). His strengths also include market engagement, reimbursement landscape evaluation, value

story creation, key opinion leader outreach, communications and advocacy.

"I am pleased to join Iovance at such an exciting time as we

catalyze and expand the commercial launch of Amtagvi and growth of Proleukin within the U.S. and beyond," said Mr. Kirby. "As

the global leader in TIL cell therapy, Iovance is strongly positioned to be the flagship cell therapy company for many thousands of patients

with solid tumor cancers for decades to come."

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. aims to be the global leader

in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a

transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer

cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's

Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell

therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please

visit www.iovance.com.

Amtagvi and its accompanying design marks, Proleukin , Iovance ,

and IovanceCares are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks

and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking

statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us,"

or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting

the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potential," "continue,"

"estimates," "anticipates," "expects," "plans," "intends," "forecast,"

"guidance," "outlook," "may," "can," "could," "might," "will,"

"should," or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking

statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception

of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking

statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such

statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future

performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual

results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied

by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ

materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S.

Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include,

but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related

to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration

("FDA") approval, and Proleukin, for which we have obtained FDA and European Medicines Agency ("EMA") approval;

the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application

submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their

potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international

markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi

and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential

for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or

at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility,

may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes

may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk

that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue

from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to

successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to,

our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other

regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including

the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results,

which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our

ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be

adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape

of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional

clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the

risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities

may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings

with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi

will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization;

the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements;

the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as

a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial

guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors,

including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press

release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no

material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this

press release; and no material fluctuation in exchange rates.

Iovance Biotherapeutics,

Sara Pellegrino, IRC

Senior Vice President, Investor Relations & Corporate Communications

650-260-7120 ext. 264

Senior Director, Investor Relations & Corporate Communications